Skip to content

Management of knee osteoarthritis with Hijamah in unani system of medicine

A randomized controlled study to evaluate the efficacy of hijamah bil shart and assessment of biomarkers in knee osteoarthritis patients

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/04/024825
Enrollment
60
Registered
2020-04-23
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M171- Unilateral primary osteoarthritisof knee

Interventions

Intervention1: Hijamah Bil shart: a total of 7 sessions for 12 weeks and each session after 14 days will be given Control Intervention1: Control Regime: 1 Paracetamol 1gm sos 2 Quadriceps and Hamstrin

Sponsors

Jamia Hamdard
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients of all genders from age 40 to 65 years 2 Patients with pain intensity score of 30 mm or more on a 100-mm visual analog scale(VAS) 3 Patients with a Kellgren & Lawrence grade of 2 and 3 on X ray Knee joint 4 Clinically stable patients 5 Patients with a BMI �30kg/m2 6 Willingness and ability to accept wet cupping intervention and to comply with the requirements of the study protocol

Exclusion criteria

Exclusion criteria: 1 Patients of bleeding disorders 2 Patients taking anticoagulants 3 Patients of anemia (Hb 4 Pregnant and lactating females 5 History of severe hypertension ,CKD, CLD and patient having HbA1c > 7 6 History of significant trauma, infection or presence of hematoma at the site of knee and/or knee surgery 7 OA of other joints other than knee 8 History of Gout, RA, Pagets disease or any other musculo- skeletal disorder 9 HbsAg, HIV, HCV positive patients 10 History of malignancy 11 Patients taking NSAIDââ?¬•s and corticosteroids, (a wash out period of 1week and 4 weeks respectively is required before enrolling patient) 12 Unwilling to participate in the study

Design outcomes

Primary

MeasureTime frame
VAS, WOMAC/ KOOS, AROM,TNF-�±, IL1- �², NTX-I, s-COMP,PIIINP, CBC, LFT, KFTTimepoint: 0 day, 84th day

Secondary

MeasureTime frame
SF 12Timepoint: 0 day, 84th day

Countries

India

Contacts

Public ContactDr Shazia Jilani

Jamia Hamdard

shaziajilani@jamiahamdard.ac.in9718764154

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026